Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study
Authors' conclusion
These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.
Study context
- Population
- Adolescents (aged 12 to <18 years) with obesity, without T2Dwithout T2D
- Participants
- 193 adolescents
- Comparison
- Once-weekly SC semaglutide 2.4 mg vs placebo
- Semaglutide 2.4 mgn = 129
- Placebon = 64reference
- Primary endpoint
- Changes in insulin sensitivity and cardiometabolic risk factors from baseline
- Follow-up
- Week 68
Methodological detailsphase 3a
- Phase 3a
Primary result
As reported in the abstract
- Semaglutide 2.4 mg vs Placebo: P = 0.0012
- Semaglutide 2.4 mg vs Placebo: P = 0.0002
- Semaglutide 2.4 mg vs Placebo: P < 0.0001
- Semaglutide 2.4 mg vs Placebo: P = 0.0181
- Semaglutide 2.4 mg vs Placebo: P = 0.0232
- Semaglutide 2.4 mg vs Placebo: P < 0.0001
- Semaglutide 2.4 mg vs Placebo: P < 0.0001
- Semaglutide 2.4 mg vs Placebo: P = 0.0105
- Semaglutide 2.4 mg vs Placebo: P < 0.0001
Further findings
| Outcome | Estimated difference (percentage points) | P value |
|---|---|---|
| Parent trial: % reduction in BMI · week 68 | −16.7 | P = 0.0001 |
Semaglutide recipients by BMI reduction ≥20% vs <20%
- Greater improvements in insulin sensitivity, glycemic measures and cardiometabolic risk factors with BMI reductions of ≥20% vs <20%
Original publication
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. Published 26 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →